We are experts in myeloma…
it’s all we do

 

Our singular focus on myeloma ensures that we bring unparalleled expertise and dedication to everything we do

 

From actionable insights to strategic engagement with leading KOLs and community clinicians, our full suite of  services empowers you to lead in the myeloma market

Everything you need to navigate the myeloma market

Insights

MYInsights provides real-time insights to data being presented at conferences or from the latest publications. Gain an understanding of how the experts view the data.

Data Compass conference reports. Collecting insights at medical conferences shouldn’t be hard. MYELOMA360 makes it easy!

Engagements

MYBoard is a new format for Advisory Boards.

In place of single company events, MYBoard is an independent full day advisory board fully managed by MYELOMA360, with four 2-hour time slots for multiple companies, allowing for a focused, efficient, dedicated session to generate insights around your strategic objectives.

Strategy & Consulting

We are a team of seasoned biopharmaceutical specialists dedicated to helping companies strategize and plan their marketing, clinical development and medical affairs activities.

Our expertise is focused in myeloma across the full development lifecycle, allowing us to provide tailored solutions to drive your company’s success.

Everything you need to navigate the myeloma market

Latest insights

Myeloma News

FDA approves Keytruda for hard-to-treat gynecological cancers

People in the U.S. with certain gynecological cancers that are resistant to first-line chemotherapies now have a new treatment option: The U.S. Food and Drug Administration (FDA) has approved the use of the immune-modulating therapies Keytruda (pembrolizumab) and...

FDA reviewing new iberdomide combo for hard-to-treat multiple myeloma

The U.S. Food and Drug Administration (FDA) is reviewing an application from Bristol Myers Squibb (BMS) seeking approval of its investigational oral therapy iberdomide for the treatment of people with hard-to-manage multiple myeloma. The application seeks approval of...

Source: Pharmacy Times articles Post Content Read More

FDA approves all-oral combo therapy for previously untreated CLL

The U.S. Food and Drug Administration (FDA) has approved the combination of two oral therapies, Venclexta (venetoclax) and Calquence (acalabrutinib), for previously untreated adults with chronic lymphocytic leukemia (CLL), a form of blood cancer. The newly approved...
Latest Data

Latest Publications

Email

info@myeloma360.com

bahisliongalabet1xbet